Article

Malignant giant solitary fibrous tumor of the mediastinum

Department of Thoracic Surgery, Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan, Brussels, Belgium.
Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer (Impact Factor: 5.8). 10/2008; 3(9):1068-70. DOI: 10.1097/JTO.0b013e318183af5d
Source: PubMed

ABSTRACT Malignant giant solitary fibrous tumor (SFT) of the mediastinum is a rare neoplasm derived from mesenchymal tissue. Owing to its large size, a complete resection of the tumor can present many challenges, particularly given its proximity to vital neighboring structures. We report a successful en-bloc resection of a massive mediastinal SFT, which was compressing the inferior trachea and heart, by means of a median sternotomy and an anterior left thoracotomy. We emphasize the rarity of this uncommon mediastinal mass. Key points of mediastinal SFT are discussed.

0 Followers
 · 
83 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: An 18-year-old man was referred to our hospital for further evaluation of a right anterior mediastinal tumor that measured 6 cm in diameter. Computed tomography-guided transcutaneous aspiration biopsy was performed, but no definitive diagnosis could be obtained. Because the tumor did not appear to be a high-grade malignant tumor, we undertook resection of the tumor to obtain a definitive diagnosis and provide appropriate treatment. Total thymectomy with tumor resection was performed through a median sternotomy. The tumor was solid, measuring 5.2 x 4.2 x 3.5 cm. The histological diagnosis was solitary fibrous tumor (SFT) arising from the mediastinum. Most extrathoracic SFTs appear to pursue a benign course, although careful long-term follow-up of these patients is necessary because the tumors have been reported to recur or metastasize in some cases.
    General Thoracic and Cardiovascular Surgery 04/2010; 58(4):205-8. DOI:10.1007/s11748-009-0510-5
  • Source
    Journal of cancer research and therapeutics 07/2011; 7(3):376-8. DOI:10.4103/0973-1482.87021 · 0.95 Impact Factor